Kytogenics Pharmaceuticals, Inc. is a drug delivery and medical products company moving aggressively to market a series of clinically significant therapies. Kytogenics' key focus is the development of products for the treatment of the mucosal disorders, Interstitial Cystitis and Inflammatory Bowel Disease, major underserved medical needs each having a market potential of over $1 Billion. Kytogenics has demonstrated the effectiveness of its formulations for delivery of important drugs, and has successfully applied its technology to the delivery of peptides and other macromolecules and more recently to the delivery of drugs to mucosal tissues. Results of studies for the oral delivery of macromolecules have shown promising early success. To bring early revenue to the Company, Kytogenics completed the pre-clinical work necessary to initiate the FDA market approval process for its materials. Kytogenics has filed four 510K submissions with the FDA and expects to file an additional six during 2008. The company has also, in Phase III Pivotal Clinical Trial, a polymeric gel product for surgical adhesion prevention.
Copyright © 2004-2009 Kytogenics Pharmaceuticals, Inc. All rights reserved.